- Our Doctors
- Dr Andrew Parsonson
Dr Andrew Parsonson
MBBS MMed (Clin Epi) FRACP AFRACMA, Medical Oncologist
Languages spoken
English, Japanese
Overview
Centres
Clinical interests
Clinical interest in breast & gastrointestinal cancer.
Dr Andrew Parsonson is a medical oncologist appointed at Nepean Hospital, Macquarie University Hospital, GenesisCare Kingswood and Hawkesbury District Hospital. His clinical interests are in breast cancers and gastrointestinal cancers. He is actively involved in the multidisciplinary care of his patients and is the current chair of the Nepean Breast Cancer MDT and is a member of the Lower Gastrointestinal Cancer MDT.
Dr Parsonson is passionate about providing the latest treatments to his patients and is an investigator on numerous international clinical trials of new medicines to treat cancer. He holds an academic appointment as a conjoint senior lecturer at the Faculty of Medicine, Health and Human Sciences at Macquarie University.
Alongside his clinical work, he is completing a part-time PhD through the Australian Institute of Health Innovation (AIHI) at Macquarie University, exploring the use of digital health to improve patient access to cancer clinical trials.
Research Interests
- Early phase clinical trials in solid tumours
- Digital Health
- Health Innovation
Professional Memberships
- Medical Oncology Group of Australia (MOGA)
- Breast Cancer Trials (BCT)
- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- Australasian Gastro-Intestinal Cancer Trials Group (AGITG)
Publications
Lemech, C., Wei, J., O’Neill, S., Huang, N., Goh, J., McCarthy, N., ... & Xu, T. (2024). 1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor.
Park, J. J., Gao, B., Beecroft, C., Wilkinson, K. J., Parsonson, A., Zhang, K., ... & Wang, N. (2024). Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study.
Parsonson, A. O., Sarkar, S., Brown, L., Low, G. K., Kiely, B. E., & Vasista, A. (2024). Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials. Asia‐Pacific Journal of Clinical Oncology, 20(6), 714-722.
O Parsonson, A., Grimison, P., Boyer, M., Horvath, L., Mahon, K., Beith, J., ... & McNeil, C. (2024). Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic. Journal of Telemedicine and Telecare, 30(2), 320-326.
Parsonson, A. O., Connolly, E., Lee, M., Hruby, G., Sandroussi, C., Merrett, N., ... & Grimison, P. (2021). Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: A multicentre observational study. ANZ Journal of Surgery, 91(11), 2447-2452.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.